Ipinzan (Metformin Hydrochloride, Vildagliptin)

Metformin decreases the liver’s production of glucose and improves insulin sensitivity in muscle and fat tissue. Vildagliptin blocks the DPP‑4 enzyme, preventing the breakdown of incretin hormones (GLP‑1 and GIP). This results in increased insulin release and reduced glucagon secretion in a glucose‑dependent manner, together lowering blood sugar levels.

The specific dose of Ipinzan is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without altering the regimen on their own.

The safety of Ipinzan in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ipinzan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control), and import documentation.

Ipinzan offers a fixed‑dose combination of metformin and a DPP‑4 inhibitor, providing complementary mechanisms in a single tablet. Compared with metformin alone, it adds incretin‑mediated glucose control, potentially achieving greater HbA1c reduction. Relative to sulfonylureas, it carries a lower risk of hypoglycaemia, while offering a convenient oral regimen.

Ipinzan tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight. Keep out of reach of children and do not use if the packaging is damaged.

Ipinzan is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their clinician and should not crush or split the tablet unless instructed.

The most serious adverse events include lactic acidosis, which can be life‑threatening, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Pancreatitis and significant hepatic dysfunction are also rare but serious. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, or severe skin reactions.

Ipinzan is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, vildagliptin, or any component of the formulation, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant liver disease or acute heart failure.